Clinical Trials Logo

Episodic Ataxia Type 2 clinical trials

View clinical trials related to Episodic Ataxia Type 2.

Filter by:
  • None
  • Page 1

NCT ID: NCT01543750 Withdrawn - Clinical trials for Episodic Ataxia Type 2

4-Aminopyridine in Episodic Ataxia Type 2

4AP in EA2
Start date: n/a
Phase: Phase 2
Study type: Interventional

Episodic ataxia type 2 (EA2) is a rare familial neurological condition characterized by debilitating episodes of vertigo and imbalance. Since the serendipitous discovery of dramatic response of EA2 to acetazolamide, acetazolamide has been the first-line treatment for EA2. Yet, for those patients who do not respond to or cannot tolerate acetazolamide, there is no alternative treatment. The purpose of this randomized trial is to test whether 4-aminopyridine may reduce the ataxia episodes in EA2 as an alternative to acetazolamide. Funding Source - FDA OOPD